Acorda Therapeutics, Inc.
ACOR
Rang in aandelen
#39156
Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering,... Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients. Globally, Ampyra is recognized and sold as Fampyra across Europe, Asia, and the Americas. Beyond its existing products, Acorda is actively advancing several experimental therapies: ARCUS for the management of acute migraine attacks, rHIgM22 which has successfully completed Phase I clinical trials for MS, and Cimaglermin alfa, currently being investigated for patients with heart failure. The company holds a licensing and collaborative agreement with Biogen Inc. for the ongoing development and market distribution of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and operates from its headquarters in Ardsley, New York.
Aandeelprijs
$0.879
Laatst gesynchroniseerd: 2024-05-07
Marktkapitalisatie
$582.38K
Verandering (1 dag)
9.88%
Verandering (1 jaar)
8,690.00%
Land
US
Handel Acorda Therapeutics, Inc. (ACOR)
Categorie
Healthcare
Operationele marge voor Acorda Therapeutics, Inc. (ACOR)
Operationele marge op October 2026 TTM: -19.78%
Volgens de meest recente financiële rapporten en aandelenkoers van Acorda Therapeutics, Inc. is de huidige operationele marge (TTM) -19.78%. Eind 2022 had het bedrijf een operationele marge van -35.45%.
Geschiedenis van de operationele marge van Acorda Therapeutics, Inc. van 2003 tot 2026
Operationele marge aan het einde van elk jaar
| Jaar | Operationele Marge | Wijzigen |
|---|---|---|
| 2026 (TTM) | -19.78% | 0.00% |
| 2023 | -19.78% | -44.20% |
| 2022 | -35.45% | -40.81% |
| 2021 | -59.89% | 5.42% |
| 2020 | -56.81% | -851.46% |
| 2019 | 7.56% | -7.35% |
| 2018 | 8.16% | -120.62% |
| 2017 | -39.57% | 471.82% |
| 2016 | -6.92% | -200.29% |
| 2015 | 6.90% | -23.84% |
| 2014 | 9.06% | 0.33% |
| 2013 | 9.03% | 7.89% |
| 2012 | 8.37% | -30.25% |
| 2011 | 12.00% | -372.11% |
| 2010 | -4.41% | -97.03% |
| 2009 | -148.63% | -3.20% |
| 2008 | -153.55% | 53.70% |
| 2007 | -99.90% | 16.43% |
| 2006 | -85.80% | -87.17% |
| 2005 | -668.73% | -92.84% |
| 2004 | -9,336.26% | 27.91% |
| 2003 | -7,298.95% | 0.00% |
Operationele marge van vergelijkbare bedrijven of concurrenten
| Bedrijf | Operationele Marge | Verschil in operationele marge | Land |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -101.16% |
IN
|
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.